Zoledronate Attenuates Angiogenic Effects of Angiotensin II-Stimulated Endothelial Progenitor Cells via RhoA and MAPK Signaling

Jin-Xiu Yang, Bin Chen, Yan-Yun Pan, Jie Han, Fei Chen, Shen-Jiang Hu*
Institute of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Abstract

**Background:** New vessel formation plays a pivotal role in the pathogenesis of neovascular-related diseases. Endothelial progenitor cells (EPCs) were found to contribute to neovascular-related diseases and interference with EPC neovascularization may be a novel target for these diseases. Zoledronate (Zol) was reported to exhibit anti-angiogenic effect. Basing on these evidences, we proposed that Zol may affect EPC function to exert novel anti-angiogenic effect. In this study, we therefore investigated the effects of Zol on multiple aspects of EPC function and explored the underlying mechanisms involved.

**Methodology/Principal Findings:** EPCs were cultured from bone marrow derived mononuclear cells. The potential effects of Zol on Angiotensin II (Ang II)-stimulated EPC proliferation, migration, adhesion, *in vitro* tube formation were investigated. The results showed that Ang II (1 μM) enhanced EPC migration, adhesion, *in vitro* tube formation but had no effect on cell proliferation. Zol (75 and 100 μM) inhibited proliferation of EPCs and 50 μM geranylgeranyol (GGOH) could reverse the decrease of EPC proliferation. We found for the first time that Zol (50–100 μM) dose dependently attenuated migration, adhesion, and *in vitro* tube formation of EPCs stimulated by Ang II. GGOH could reverse the attenuation of EPC function induced by Zol. However, Zol did not induce EPC apoptosis. In addition, the underlying mechanisms were determined. The results revealed that Zol markedly down-regulated active RhoA stimulated by Ang II and inhibited the phosphorylation of Erk1/2 and JNK. Moreover, RhoA silencing resulted in a notable inhibition of EPC *in vitro* tube formation, suggesting that RhoA suppression played a pivotal role in Zol antiangiogenic effect.

**Conclusions/Significance:** These findings suggested that Zol attenuated the promotion of EPC function stimulated by Ang II and exhibited novel antiangiogenic effect via RhoA and MAPK signaling. Thus, Zol may be served as a novel therapeutic agent for neovascular-related diseases treatment.

Citation: Yang J-X, Chen B, Pan Y-Y, Han J, Chen F, et al. (2012) Zoledronate Attenuates Angiogenic Effects of Angiotensin II-Stimulated Endothelial Progenitor Cells via RhoA and MAPK Signaling. PLoS ONE 7(10): e46511. doi:10.1371/journal.pone.0046511

Editor: Gian Paolo Fadini, University of Padova, Medical School, Italy

Received: March 30, 2012; Accepted: August 31, 2012; Published: October 11, 2012

Copyright: © 2012 Yang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research project has been supported by the National Natural Science Foundation of China (NSFC 81170242, 30470715 and 30870939). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: s0hu0001@hotmail.com

Introduction

Neovascularization is involved in lots of disorders including diabetic retinopathy [1], cancer [2] and rheumatoid arthritis [3]. Also there is evidence that new vessel formation plays a pivotal role in the pathogenesis of atherosclerosis [4,5]. Furthermore, the extent of vasa vasorum neovascularization correlates with severity of atherosclerosis [6,7]. Recent studies have indicated that endothelial progenitor cells (EPCs) contributed to those pathological angiogenesis [6,9,10,11].

EPCs comprise a group of cells that have the capacity to circulate, proliferate and differentiate into mature endothelial cells (ECs) but that have not yet acquired characteristic mature endothelial markers nor formed a lumen [12]. These precursor cells not only participate in angiogenesis, but also contribute to postnatal vasculogenesis [12,13]. Interference with EPC neovascularization may be a novel target for neovascular-related diseases.

Angiotensin II (Ang II), the main effector of the renin-angiotensin system, has emerged as one of the essential links in the pathophysiology of many neovascular-related diseases such as atherosclerosis and cancer. Ang II was produced increasely within atherosclerotic lesions [14], and was found to induce atherosclerotic plaque vulnerability [15]. Ang II was found to be involved in many types of cancer [16,17]. Emerging evidence indicated that Ang II increased vessel density and activated angiogenesis [18], thus may aggravate the process of neovascular-related diseases.

Zoledronate (Zol), a third-generation bisphosphonate, has already been approved for clinical use in the treatment of hypercalcemia caused by malignancy [19]. Zol was found to improve atherosclerotic risk index [20] and the prognosis of cancer [21]. Recent studies demonstrated the antiangiogenic effect of Zol [22]. Thus, antiangiogenesis may contribute to Zol protective effects on neovascular-related diseases. It was proposed that Zol exerted antiangiogenic effect through its impact on various
angiogenic properties of ECs [23]. Wood et al. reported that Zol could impair EC proliferation, induce EC apoptosis, and modulate EC migration and adhesion, thus exerting antiangiogenic effect [24]. Yamada et al. found that Zol impaired EPC differentiation in a dose-dependent manner, the effect was observed even at low concentrations [22]. At high drug levels, Zol also induced EPC apoptosis [22]. These data suggested that Zol may influence EPC function. However, a thorough analysis of the effect of Zol on multiple aspects of EPC function, especially the molecular mechanisms involved has not been undertaken.

It was found that Zol modulated mevalonate pathway and affected small-G-protein prenylation [25]. RhoA is a very important member of small-G-protein and its most widely studied effector protein is Rho-associated kinases (ROCK) [26]. RhoA/ROCK plays an important role in angiogenesis and may be a significant target for antiangiogenic treatment [26]. RhoA/ROCK has also been indicated as an upstream regulator of mitogen-activated protein kinase (MAPK) family members including extracellular signal-regulated protein kinase (ERK), c-Jun-NH2 kinase (JNK), and p30 MAPK (p30) [27,28,29].

Therefore, in this study we investigated the potential effects of Zol on the function of Ang II-stimulated EPCs, and also explored the role of RhoA and MAPK signaling in this process.

Materials and Methods

Isolation and cultivation of EPCs

Our study was approved by the institutional animal care committee of Zhejiang University (approval ID: SYXK 2007–2122). Male Sprague-Dawley rats of 6 to 7 weeks old (200 g) were fed with conventional diet.

In vitro expansion of rat bone marrow-derived EPCs was performed as recently described [30]. Briefly, EPCs were collected from the femurs of 6 to 7 weeks old male Sprague-Dawley rats (200 g). The mononuclear cells (MNCs) fraction was obtained by density gradient centrifugation. Cells were then suspended in EBM-2 medium (Lonza) supplemented with 10% FBS (Gibico) and plated on 6-well plates (Corning). After 24 h the non-adherent cells were aspirated and transferred to new plates. After another 24 h this procedure was repeated to remove rapidly adherent mature ECs and hematopoietic cells being possibly present in the aspirate. Only the non-adherent cells harvested after 48 h were evaluated further in all experiments. This fraction was cultured in EBM-2 medium supplemented with EGM-2 MV single aliquots containing 10% FBS, vascular endothelial growth factor (VEGF), epidermal growth factor, fibroblast growth factor-2, insulin-like growth factor-1 (IGF-1) and ascorbic acid. Non-adherent cells were removed by washing after 4 d in culture and new media was applied every 3 days.

EPC fluorescent staining

Fluorescent chemical detection of EPCs was performed on attached MNCs after 14 d in culture. Direct fluorescent staining was used to detect dual binding of 1, 1- dioctadecyl-3, 3, 3, 3-tetramethylindocarbocyanine (DiI)-labeled acetylated low-density lipoprotein (acLDL; Molecular Probe) and fluorescein isothiocyanate (FITC)-conjugated Ulex europaeus agglutinin (UEA)-1 (Sigma). The cells were first incubated with acLDL (2.4 μg/ml) at 37°C and later fixed with 2% paraformaldehyde for 10 min. After washing, EPCs were reacted with UEA-1 (10 μg/ml) for 1 h. After staining, samples were viewed with fluorescence microscopy (×200). Fluorescence microscopy identified double-positive cells as EPCs.

Flow cytometry cell analysis

To identify EPCs, the cells were trypsinized, followed by repeated gentle flushing through a pipette tip. Cells (2×10^4) were incubated for 30 min at 4°C with anti-vascular endothelial growth factor receptor 2 (anti-VEGFR2, Abcam) and phycoerythrin-conjugated monoclonal antibodies against CD31 (R&D), and von Willebrand factor (vWF, Abcam). A FITC-conjugated antimouse antibody (Vector) was added for staining with VEGFR2. Isotype-identical antibodies served as controls. Flow cytometric analyses were performed by using a FACStar flow cytometer (Beckman Coulter).

Cell proliferation assay

The effect of Zol and Ang II on EPC proliferation was determined by 3-(4, 5-dimethylthiazol -2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Cells were digested with 0.25% trypsin and then cultured in EBM-2 medium containing 10% FBS in 96-well culture plate (200 μl/well). After being cultured for 48 h, the supernatant was discarded by aspiration and serum-free EBM-2 medium was added (200 μl/well). Zol (0, 25, 50, 75, and 100 μM) was added respectively. Geranylgeranylated (GGOH) is metabolized to geranylgeranylpyrophosphate (GGPP) and is used to form geranylgeranylated Rho. It is reported that Zol reduced the synthesis of GGPP and GGOH might restore the reduction of GGPP [31]. Therefore, the group of Zol combined with GGOH was also established. After being incubated for 30 min, EPCs of each well were treated with Ang II (1 μM) and cultured for 48 h. Then they were supplemented with 20 μl MTT (5 g/l, Fluka Co. Product) and incubated for another 4 h. The supernatant was aspirated and the EPCs preparation was shaked with 150 μl dimethyl sulfoxide (DMSO) for 10 min, before the OD value was measured at 490 nm.

Migration assay

EPC migration was evaluated by using a transwell chamber (Bioscience) with 8-μm pore filters. In brief, isolated cells were detached using 0.25% trypsin, harvested by centrifugation, resuspended in 500 μl EBM-2 medium and counted, then 2×10^4 EPCs were placed in the upper chamber of a transwell chamber. VEGF in serum-free EBM-2 medium was placed in the lower compartment of the chamber. After 24 h incubation at 37°C in 5% humidified CO2, the lower side of the filter was washed with PBS and cells remaining on the upper face were removed with a cotton wool swab. Transwell filters were fixed with 2% paraformaldehyde. For quantification, EPCs were stained with 0.1% crystal violet solution. Cells migrating into the lower chamber were counted in five random microscopic fields (×200).

EPC adhesion assay

After incubating with Zol, Ang II and GGOH overnight, EPCs were washed with PBS and gently detached with 0.25% trypsin. After centrifugation and resuspension in EBM-2 medium, identical cells were replated onto fibronectin-coated culture dishes and incubated for 30 min at 37°C in 5% humidified CO2. Adherent cells were counted by independent blinded investigators in five randomly chosen microscopic fields (×400) [31].

In vitro tube formation assay

Endothelial tube formation was assessed with the use of Matrigel assay (Millipore), according to the manufacturer’s instructions. Briefly, ECMATRIX™ solution was thawed on ice overnight, mixed with 10×ECMATRIX™ diluent and placed in a 96-well plate at 37°C for 1 h to allow the matrix solution to
solidify. EPCs were stained with Dil-acLDL (Molecular Probes, 5 µg/ml) for 1 h. Then EPCs (1×10⁴ cells) were harvested and replated on top of the solidified matrix solution with 150 µl EBM-2 medium. Cells were incubated at 37°C for 18 h and fixed with 2% paraformaldehyde. The lengths of enclosed tubes within the network were measured from five random microscopic fields (×200). The experiment was repeated 5 times.

**EPC apoptosis assay**

The externalization of phosphatidylserine during apoptosis was evaluated by FITC-conjugated annexin-V and propidium iodide (PI) staining by using an Annexin V-FITC Apoptosis Kit (KeyGEN). After the indicated time, 5×10⁵ cells treated or untreated were harvested, washed twice with PBS, cells were re-suspended in 500 µl binding buffer and 5 µl FITC-labeled...
annexin-V and 5 μl PI solution were added. Then tubes were kept on ice for 10 min and then subjected on the flow cytometer (Beckman Coulter) which was settled on cells gated on the basis of their forward and side light scatter with any cell debris excluded from analysis. The gated cells were then plotted for FITC-conjugated annexin-V and PI in a 2-way dot plot to assess percentage of apoptotic cells.

Lentivirus vectors for RhoA small hairpin RNA and cell infection

A third generation self-inactivating lentivirus vector containing a CMV-driven GFP reporter and a U6 promoter upstream of the cloning restriction sites (BamHI and EcoRI) was used. Four coding regions corresponding to targeting rat RhoA starting at positions 153, 81, 354 and 40 in the sequence (GenBank Accession: NM_057132.3) were selected as siRNA target sequences under the guide of siRNA designing software offered by GenePharma Co., Ltd, Shanghai, China. Four shRNA-RhoA lentivirus vectors were respectively constructed by Genepharma. The Lv-NC-shRNA which included the GFP gene was designed with a randomly chosen nonsense sequence to serve as negative control. The most active shRNA against the rat RhoA target DNA sequence, 5’-GATCCCGAGGTAGGTTCGCGACTTCTACCTGCTTTTTT3’, which starting at position 153 was selected. Recombinant lentivirus vectors were produced by co-transfecting 293T cells with the lentivirus expression plasmid and packaging plasmids. The virus titers produced were approximately 10⁹ transducing U/ml medium.

When the cells were about 80% confluent in EBM-2 medium, they were detached and subcultured at 1×10⁶ cells per well into six-well plates. After 24 h culture, cells were infected with recombinant lentivirus vectors at a multiplicity of infection (MOI) of 100. Polybrene was added to each well at a concentration of 5 μg/ml.

RhoA activity assay

RhoA activity was determined by pull-down assay using a Rho activation assay kit (Cytoskeleton) [32]. EPCs were grown to 60% confluence in 100-mm dishes and then placed in serum-free EBM-2 medium for 12 h. Cells were stimulated with 1 μM Angiotensin II (Ang II) for 15 min at 37°C. Zol (50 μM) with or without GGOH (50 μM) were added 48 h before stimulation. Cells were then lysed with lysis buffer and a protein assay was performed prior to the pull-down assay to equalize total protein concentration in each treated group. Whole cell lysates were incubated with agarose-conjugated rhotekin-RBD at 4°C for 60 min and then washed twice with wash buffer. Agarose beads were boiled in SDS-PAGE sample buffer to release active Rho prior to undergoing precipitation with the Rhotekin GTP-Rho. After precipitation bound Rho proteins were detected by Western blotting using a specific anti-RhoA antibody (Cytoskeleton). Meanwhile, 20 μg total cell lysate per sample was used to detect the total amount of RhoA.

Western blotting assay

EPCs were grown to 60% confluence in 6 well plate and then placed in serum-free EBM-2 medium for 12 h. Cells were stimulated with 1 μM Ang II for 15 min at 37°C. Zol (50 μM) with or without GGOH (50 μM) were added 48 h before stimulation. The protein contents of the cell lysates were determined using a micro BCA kit (Beyotime). Protein from cell lysates was mixed with 4×loading buffer (Invitrogen) and boiled...
for 10 minutes, before electrophoresis on 10% sodium dodecyl sulfate-polyacrylamide gels. Following transfer onto polyvinylidene fluoride membranes and blocking, membranes were incubated with antibodies against RhoA, phospho-p38, p38, phospho-JNK, JNK, phospho-ERK1/2 and ERK1/2 (1:1000, Cell Signaling). Following three washes in TBST, membranes were subsequently incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (1:2500, MultiSciences). The signals were detected by enhanced chemiluminescence reagents (Thermo) and exposure to X-ray film. The density of the bands was quantified by using Image J software (National Institutes of Health). Expression of RBD binding RhoA was normalized to total RhoA expression in the same lane and phospho-p38, JNK, ERK1/2 were normalized to total p38, JNK and ERK1/2 respectively. Data from each experiment were presented as percent of control group. In the siRNA experiment, expression of RBD binding RhoA and total RhoA was normalized to β-actin expression in the same lane.

Figure 4. Adhesion capacity of EPCs treated with Ang II and Zol. Ang II increased EPC adhesion capacity, while Zol dose dependently decreased cell adhesion and GGOH showed reversal effect. Data are presented as mean ± SD, n = 5. &P < 0.05 vs. control group; * P < 0.05 vs. Ang II group; # P < 0.05 vs. 50 μM Zol+Ang II group. doi:10.1371/journal.pone.0046511.g004

Figure 5. Effect of Ang II and Zol on EPC in vitro tube formation ability. Ang II increased EPC in vitro tube formation ability, while Zol dose dependently decreased cell in vitro tube formation and GGOH showed reversal effect. A: Quantitative analysis of total length of the tubes formed on Matrigel for each experimental group. B: Light micrographs showing typical tubules (200x). Results are the mean ± SD, n = 5. &P < 0.01 vs. control group; * P < 0.05 vs. Ang II group; ** P < 0.01 vs. Ang II group; # P < 0.05 vs. 50 μM Zol+Ang II group. doi:10.1371/journal.pone.0046511.g005
Effect of Zol on the proliferation of Zol-pretreated EPCs followed by Ang II stimulation

EPC proliferation was measured using the MTT assay (Figure 2). Ang II had no effect on EPC proliferation. Zol reduced EPC proliferation in the absence or presence of 50 μM Zol were combined with or without 50 μM GGOH before incubation with 1 μM Ang II for 15 min. RBD-RhoA proteins were detected by Western blot using monoclonal antibody against RhoA (upper panel), Western blotting of the total amount of RhoA in cell lysates (lower panel) was also performed in the same lysates. The results are representative of three independent experiments. * P<0.01 vs. control group; ** P<0.01 vs. Ang II group; &P<0.01 vs. Zol+Ang II group.

doi:10.1371/journal.pone.0046511.g006

Statistical analysis

All data are presented as mean ± SD. Differences between group means were assessed by ANOVA for multiple comparisons using SPSS 16.0. Values of P<0.05 were considered significant.

Results

Characterization of EPCs

Total MNCs isolated and cultured for 14 d resulted in a spindle-shaped, ECs-like morphology (Figure 1A). EPCs were characterized as adherent cells double positive for DiLDL uptake and lectin binding by using fluorescence microscopy (Figure 1B–D). These cells were characterized further by demonstrating the expression of CD31, VEGFR2 and vWF by flow cytometry (Figure 1E–G).

Effect of Zol on the proliferation of Zol-pretreated EPCs followed by Ang II stimulation

EPC proliferation was measured using the MTT assay (Figure 2). Ang II had no effect on EPC proliferation. Zol reduced EPC proliferative activity, which became apparent at 75 and 100 μM (75 μM Zol+Ang II: 84.83±6.73% of control, 100 μM Zol+Ang II: 80.93±8.36% of control, P<0.05). Although there was no significant statistical difference (P>0.05), GGOH (50 μM) could partly reverse the reduction in EPC proliferation induced by 50 μM Zol (50 μM Zol+Ang II vs. 50 μM Zol+Ang II+50 μM GGOH: 88.37±4.74% of control vs. 99.41±5.94% of control). GGOH (50 μM) could reverse the decreased proliferation of 75 and 100 μM Zol-pretreated EPCs followed by 1 μM Ang II-stimulation (P<0.05, Figure S1).

Effect of Zol on the migration of Zol-pretreated EPCs followed by Ang II stimulation

EPC migration was analyzed by the transwell chamber assay (Figure 3). The result showed that Ang II promoted EPC migration (control vs. Ang II: 76.8±14.3 vs. 109.2±18.3, P<0.05). Zol dose dependently decreased EPC migration, which became apparent at 50 μM (Ang II vs. 50 μM Zol+Ang II: 109.2±18.3 vs. 80.2±15.1, cells per high-powered field, P<0.01), with a peak at 100 μM (Ang II vs. 100 μM Zol+Ang II: 109.2±18.3 vs. 66.4±14.9, P<0.01). GGOH (50 μM) could reverse the decrease of EPC migration capacity induced by 50 μM Zol (50 μM Zol+Ang II vs. 50 μM Zol+Ang II+50 μM GGOH: 80.2±15.1 vs. 101.2±17.2, P<0.05).

Effect of Zol on the adhesion of Zol-pretreated EPCs followed by Ang II stimulation

To study the possibility that Zol alter adhesion of EPCs, cells were incubated with Zol (at a serial of concentration: 0, 25, 50, 75, and 100 μM) and Ang II (1 μM) for 48 h. After replating on fibronectin-coated dishes, EPCs preexposed to Ang II exhibited a significant increase in the number of adhesive cells (control vs. Ang II: 47.6±10.1 vs. 63.0±12.0, P<0.05). EPC adhesion ability was attenuated by Zol in a dose dependent manner, which became apparent at 25 and 50 μM (Ang II vs. 25 μM Zol+Ang II: 63.0±12.0 vs. 51.8±9.4; Ang II vs. 50 μM Zol+Ang II: 63.0±12.0 vs. 48.2±9.1, P<0.05), with a peak at 100 μM (Ang II vs. 100 μM Zol+Ang II: 63.0±12.0 vs. 38.8±7.9, P<0.01) (Figure 4). GGOH (50 μM) could reverse the attenuation of EPC adhesion ability induced by 50 μM Zol (50 μM Zol+Ang II vs. 50 μM Zol+Ang II+50 μM GGOH: 48.2±9.1 vs. 61.0±5.4, P<0.05) (Figure 4).

Effect of Zol on the migration of Zol-pretreated EPCs followed by Ang II stimulation

EPCs were incubated overnight in starvation medium and then stimulated for 48 h with Zol and Ang II in basal medium. EPCs were incubated with Zol (at a serial of concentration: 0, 25, 50, 75, and 100 μM) for 48 h. After replating on fibronectin-coated dishes, EPCs preexposed to Ang II exhibited a significant increase in the number of adhesive cells (control vs. Ang II: 47.6±10.1 vs. 63.0±12.0, P<0.05). EPC adhesion ability was attenuated by Zol in a dose dependent manner, which became apparent at 25 and 50 μM (Ang II vs. 25 μM Zol+Ang II: 63.0±12.0 vs. 51.8±9.4; Ang II vs. 50 μM Zol+Ang II: 63.0±12.0 vs. 48.2±9.1, P<0.05), with a peak at 100 μM (Ang II vs. 100 μM Zol+Ang II: 63.0±12.0 vs. 38.8±7.9, P<0.01) (Figure 4). GGOH (50 μM) could reverse the attenuation of EPC adhesion ability induced by 50 μM Zol (50 μM Zol+Ang II vs. 50 μM Zol+Ang II+50 μM GGOH: 48.2±9.1 vs. 61.0±5.4, P<0.05) (Figure 4).

Effect of Zol on the in vitro tube formation of Zol-pretreated EPCs followed by Ang II stimulation

EPCs were incubated overnight in starvation medium and then stimulated for 48 h with Zol and Ang II in basal medium. EPCs were incubated with Zol (at a serial of concentration: 0, 25, 50, 75, and 100 μM) for 48 h. After replating on fibronectin-coated dishes, EPCs preexposed to Ang II exhibited a significant increase in the number of adhesive cells (control vs. Ang II: 47.6±10.1 vs. 63.0±12.0, P<0.05). EPC adhesion ability was attenuated by Zol in a dose dependent manner, which became apparent at 25 and 50 μM (Ang II vs. 25 μM Zol+Ang II: 63.0±12.0 vs. 51.8±9.4; Ang II vs. 50 μM Zol+Ang II: 63.0±12.0 vs. 48.2±9.1, P<0.05), with a peak at 100 μM (Ang II vs. 100 μM Zol+Ang II: 63.0±12.0 vs. 38.8±7.9, P<0.01) (Figure 4). GGOH (50 μM) could reverse the attenuation of EPC adhesion ability induced by 50 μM Zol (50 μM Zol+Ang II vs. 50 μM Zol+Ang II+50 μM GGOH: 48.2±9.1 vs. 61.0±5.4, P<0.05) (Figure 4).

Effect of Zol on EPC apoptosis

We used the Annexin V-FITC Apoptosis Kit to investigate the effect of Zol on EPC apoptosis. The result showed that EPC apoptosis was not affected by Zol (Figure S2).

Effect of Zol on RhoA activation of Zol-pretreated EPCs followed by Ang II stimulation

We used a pull-down assay with the fusion protein GST-RBD, which specifically recognizes Rho-GTP, the active form of Rho to investigate the effect of Zol on RhoA activation of Zol-pretreated EPCs followed by Ang II stimulation. Rho-GTP increased in
EPCs treated with Ang II for 15 min. The active form of RhoA (GTP-bound) was elevated to 160.57 ± 12.98% of control after the addition of Ang II (Figure 6). Pretreatment with 50 μM Zol markedly reduced RhoA activation to 49.19 ± 7.79% of control (P < 0.01). In the presence of 50 μM GGOH, the inhibitory effect of Zol against the activation of RhoA by Ang II was markedly reversed to 72.94 ± 6.19% of control, but was still significantly lower than the Ang II group (Figure 6). These results suggest that RhoA activation is partially attenuated by Zol via the inhibition of geranylgeranylation.

RhoA suppression played a pivotal role in Zol antiangiogenic effect

To explore the role of RhoA signaling in the antiangiogenic effect of Zol, we used shRNA to silence RhoA gene expression and investigated its effect on EPC in vitro tube formation. The data showed that the expression of both total and active form of RhoA was markedly reduced in EPCs that pretreated with 50 μM Zol (P < 0.01). In the presence of 50 μM GGOH, the inhibitory effect of Zol against the activation of RhoA by Ang II was markedly reversed to 72.94 ± 6.19% of control, but was still significantly lower than the Ang II group (Figure 6). These results suggest that RhoA activation is partially attenuated by Zol via the inhibition of geranylgeranylation.

Zoledronate Attenuates Angiogenic Effects of EPCs

Zol inhibited JNK and ERK phosphorylation

To investigate the molecular mechanisms further, MAPK pathway was detected in each group using western blot analysis. Erk1/2 phosphorylation was increased to 352.33 ± 36.19% of control and JNK phosphorylation was promoted to 252.99 ± 18.39% of control after administration of 1 μM Ang II. The phosphorylation of Erk1/2 and JNK was markedly reduced in EPCs that pretreated with 50 μM Zol (P < 0.01). In the presence of 50 μM GGOH, the inhibitory effects of Zol against the phosphorylation of Erk1/2 and JNK were reversed significantly (Figure 8). Neither total Erk 1/2 nor JNK was changed. There was no obvious influence of Zol on p38 phosphorylation (data not shown). These results suggest the involvement of Erk1/2 and JNK signal pathway in the role of Zol effects on EPCs.

Discussion

The regulation of neovascularization is an important therapeutic target in neovascular-related diseases. There is considerable data implicating a role for Ang II in the atherogenic process [35]. Vasa vasorum neovascularization plays a pivotal role in the pathogenesis of atherosclerosis [6,7]. Ang II was also found to be involved in many types of cancer [16,17]. EPCs participate in pathological angiogenesis which is implicated in the pathogenesis of neovascular-related diseases such as atherosclerosis [3] and cancer [34]. So it is probable that Ang II may contribute to the aggravation of neovascular-related diseases through affecting EPC angiogenic-related function.
In this study, we found that EPC migration, adhesion capacity, and in vitro tube formation ability were promoted by 1 μM Ang II, although EPC proliferation was not affected by Ang II. These findings suggested that Ang II participated in the process of neovascular-related diseases by affecting EPC function, and interference with these function may represent a promising therapeutic strategy in the treatment of neovascular-related diseases.

Zoledronate (Zol), a third-generation bisphosphonate, was seen to improve atherosclerotic risk index [20] and the prognosis of cancer [21]. Zol may have potential therapeutic effects on the treatment of atherosclerosis and tumor. Recent studies have demonstrated anti-angiogenic properties of Zol [22], which may contribute to its protective effects on the treatment of atherosclerosis and tumor. However, the precise mechanisms of anti-angiogenic properties of Zol have not yet been fully clarified.

In present study, we investigated the effects of Zol on function of EPCs stimulated by Ang II. We have demonstrated for the first time that Zol was able to significantly attenuate EPC function, thus exerting anti-angiogenic effect. We found that Zol decreased EPC proliferative activity, and the effect could be reversed by GGOH. In cells, GGOH is metabolized to GGPP which is reduced by Zol [35]. Zol also reduced the promotion of EPC migration ability and adhesion capacity induced by 1 μM Ang II, while GGOH showed reversal effect. The observation that Zol affected EPC proliferation, migration, and adhesion prompted us to investigate the possibility that Zol could also inhibit angiogenic ability. In vitro tube formation assay was performed to investigate the effect of Zol on EPC angiogenic ability. The results showed that EPC in vitro tube formation was profoundly down-regulated by Zol in a concentration-dependent manner, which became apparent at 50 μM, with a peak at 100 μM. The effect on EPCs was reversed by incubating with 50 μM GGOH. The effect of Zol (25, 50, 75, and 100 μM) on EPC apoptosis was also investigated. The data showed that Zol did not affect EPC apoptosis even at 100 μM, confirming that the decrease in proliferation, migration, adhesion, and in vitro tube formation of EPCs treated with Zol was not due to apoptosis of the cells.

Zol is one kind of nitrogen containing bisphosphonates, which inhibits the mevalonate pathway [36,37]. This pathway is significant for the production of small G proteins, such as Rho, Ras and Rac proteins, which are essential for intracellular structure and function [38,39]. Substantial proof has accumulated that the Rho proteins play an important role in angiogenesis [40,41]. It is imperative that we further explore this signaling pathway, as it may be served as an excellent therapeutic target for diseases of aberrant angiogenesis. RhoA (the predominant isoform of Rho: A, B, C) acts as a molecular switch cycling between an inactive guanosine diphosphate (GDP)-bound and an active guanosine triphosphate (GTP)-bound form [42,43]. RhoA and
its effector protein ROCK regulate downstream effectors of MAPK family members including ERK, JNK, and p38 [27,28,29]. Ang II was also found to activate RhoA/ROCK signaling [28]. In this study, we further explored the role of RhoA and MAPK signaling in novel angiogenic effect of Zol on EPCs stimulated by Ang II.

The active form of Rho (GTP-bound) was elevated after the addition of Ang II. Pretreatment with Zol markedly reduced RhoA activation. In the presence of GGOH, the inhibitory effect of Zol against the activation of RhoA by Ang II was markedly reversed. These results suggested that RhoA activation was attenuated by Zol via the inhibition of geranylgeranylation. Our data also showed that the phosphorylation of Erk1/2 and JNK was increased remarkably compared to control group after administration of Ang II. Zol reduced the phosphorylation of Erk1/2 and JNK of EPCs. GGOH significantly reversed the inhibitory effects of Zol against the phosphorylation of Erk1/2 and JNK. These results suggest the involvement of Erk1/2 and JNK signal pathway in the role of Zol antiangiogenic property. Several studies have shown that MAPK pathway was involved in angiogenesis [44]. Ang II was found to activate MAPK and through this pathway elicited many cellular responses [45]. RhoA/ROCK has also been indicated as an upstream regulator of MAPK family members [27,28,29]. Our data suggest that the novel antiangiogenic effect of Zol might be through impairing EPC function via RhoA and MAPK signaling. The direct relationship between these findings was further confirmed by the use of shRNA to silence RhoA gene expression. The data showed that the expression of both total and active form of RhoA was decreased markedly in RhoA shRNA interference group compared with control shRNA interference group. Meanwhile, RhoA silencing resulted in a notable inhibition of EPC in vitro tube formation. These results suggested that RhoA suppression played a pivotal role in Zol antiangiogenic effect.

It is worthy to note that the cells cultured in this study were not colony forming unit-Hill (CFU-Hill), although the culture method was similar. CFU-Hill cells were first defined by Hill et al. in 2003 [46]. Human peripheral blood MNCs were resuspended in Medium 199 growth medium and plated on plates coated with human fibronectin. Non-adherent cells were collected 48 hours later and replated onto new fibronectin-coated plates. Seven days later, the numbers of EPCs colony-forming units were counted. The cells cultured in our study have a different origin from that of CFU-Hill cells. In addition, the culture process of the cells was not the same.

In the study, we cultured EPCs with MNCs derived from healthy rats to investigate the antiangiogenic effects of Zol on EPCs in the presence of Ang II. However, if we wanted to study the antiangiogenic effects of Zol on EPCs in atherosclerosis, we should use MNCs derived from atherosclerotic animals. As well, we should test in vivo whether Zol could attenuate EPC-induced neovascularization for vasa vasorum of atherosclerotic plaque.

In conclusion, our data showed that Ang II enhanced EPC migration, adhesion, and in vitro tube formation. Zol could reverse these effects and reduce cell proliferation, thus exhibiting novel antiangiogenic effect. RhoA and MAPK signaling may be involved in these processes.

Supporting Information

Figure S1 Effect of GGOH on the proliferation of Zol-pretreated EPCs followed by Ang II-stimulation. EPC proliferation was decreased in presence of Zol (75 and 100 μM) and 1 μM Ang II, and could be reversed by 50 μM GGOH. Data are presented as mean ± SD, n = 5. * P<0.05 vs. Ang II group; #P<0.05 vs. 75 μM Zol+Ang II group; ## P<0.05 vs. 100 μM Zol+Ang II group. (TIF)

Figure S2 Effect of Zol on EPC apoptosis. (A) Representative dot-plots of apoptotic cells cocultured with different concentrations of Zol. (B) Zol did not affect EPC apoptosis. Data are presented as mean ± SD, n = 3, P>0.05. (TIF)

Author Contributions

Conceived and designed the experiments: S-JH J-XY. Performed the experiments: J-XY Y-YP. Analyzed the data: J-XY BC. Contributed reagents/materials/analysis tools: J-XY JH FC. Wrote the paper: S-JH J-XY.

References

1. Folkman J (1995) Clinical applications of research on angiogenesis. N Engl J Med 333: 1573–1576.
2. Sonveaux P, Copetti T, De Saredeleer CJ, Vegrav F, Verrax J, et al. (2012) Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis. PLoS One 7: e33418.
3. Sama M (2006) Role of circulating vascular progenitors in angiogenesis, vascular healing, and pulmonary hypertension: lessons from animal models. Arterioscler Thromb Vasc Biol 26: 1080–1014.
4. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, et al. (2003) Inhibition of platelet neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 100: 4736–4741.
5. Khurana R, Simons M, Martin JF, Zachary IC (2005) Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 112: 1813–1824.
6. Sueishi K, Yonemitsu Y, Nakagawa K, Kaneda Y, Kumamoto M, et al. (1997) Angiotensin II mediates transendothelial migration through interaction with the thrombin receptor in human microvascular endothelial cells. J Clin Invest 100: 1859–1866.
7. Wilson SH, Herrmann J, Lerman LO, Holmes DR Jr, Napoli C, et al. (2002) Simvastatin preserves the structure of coronary adventitial vasa vasorum in human atherosclerosis and angiogenesis. Its pathophysiological significance in humans and its potential as a source for therapeutic vasculogenesis? J Cell Mol Med 8: 509–518.
8. Asahara T, Marohasa T, Sullivan A, Silver M, van der Zee R, et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964–967.
9. Ichiki T (2004) Role of renin angiotensin system in angiogenesis: it is still elusive. Drug Targets 11: 412–420.
10. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD (1998) Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 98: 800–807.
11. Mazzolai L, Duchosal MA, Korber M, Bouzourene K, Aubert JF, et al. (2004) Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice. Hypertension 44: 277–282.
12. Ino K, Shiibata K, Yamamoto E, Kajiyama H, Nawa A, et al. (2011) Role of the renin-angiotensin system in gynecologic cancers. Curr Cancer Drug Targets 11: 405–411.
13. Bleuzen O, Hammon M, Naschberger E, Lipnik K, Arkudas A, et al. (2011) Endothelial progenitor cells: a source for therapeutic vasculogenesis? J Cell Mol Med 15: 4192–4199.
14. Potter DD, Sobbey CG, Tompkins PK, Rossen JD, Heistad DD (1998) Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 98: 800–807.
15. Li CX, Shao Y, Ng KT, Liu XB, Ling CC, et al. (2012) FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. PLoS One 7: e32800.
16. Hu Y, Davison F, Zhang Z, Xu Q (2003) Endothelial replacement and angiogenesis in atherosclerotic lesions of alografts are contributed by circulating progenitor cells. Circulation 108: 3122–3127.
17. Rumpold H, Wolf D, Koeck R, Gunsilius E (2004) Endothelial progenitor cells: a source for therapeutic vasculogenesis? J Cell Mol Med 8: 509–518.
18. Asahara T, Marohasa T, Sullivan A, Silver M, van der Zee R, et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964–967.
19. Bleuzen O, Hammon M, Naschberger E, Lipnik K, Arkudas A, et al. (2011) Endothelial progenitor cells are integrated in newly formed capillaries and after adjacent fibrovascular tissue after subcutaneous implantation in a fibrin matrix. J Cell Mol Med 15: 2452–2461.
20. Porter DD, Sobbey CG, Tompkins PK, Rossen JD, Heistad DD (1998) Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 98: 800–807.
21. Mazzolai L, Duchosal MA, Korber M, Bouzourene K, Aubert JF, et al. (2004) Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice. Hypertension 44: 277–282.
22. Ino K, Shiibata K, Yamamoto E, Kajiyama H, Nawa A, et al. (2011) Role of the renin-angiotensin system in gynecologic cancers. Curr Cancer Drug Targets 11: 405–411.
23. Lau SF, Leung PS (2011) Role of the RAS in pancreatic cancer. Curr Cancer Drug Targets 11: 412–420.
24. Ichiki T (2004) Role of renin angiotensin system in angiogenesis: it is still elusive. Arterioscler Thromb Vasc Biol 24: 622–624.
19. Kawada K, Minami H, Okabe K, Watanabe T, Inoue K, et al. (2005) A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol 35: 28–33.

20. Gozzetti A, Gennari L, Merlotti D, Salvadori S, De Paola V, et al. (2008) The effects of zoledronic acid on serum lipids in multiple myeloma patients. Calcif Tissue Int 82: 258–262.

21. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, et al. (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma [MRC Myeloma IX]: a randomised controlled trial. Lancet 367: 1989–1999.

22. Yamada J, Tsuno NH, Kimiyama J, Tsuchiya H, Yoneyama T, et al. (2009) Antiangiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res 151: 115–120.

23. Yuasa T, Kimura S, Ashihara E, Habsch T, Markawa T (2007) Zoledronic acid - a multiplicity of anti-cancer action. Curr Med Chem 14: 2126–2135.

24. Bryan BA, D’Amore PA (2007) What tangled webs they weave: Rho-GTPase signaling axis. Mol Cell Physiol 300: C1181–1192.

25. Coscia M, Quaglino E, Iezzi M, Carcio C, Pantaleoni F, et al. (2011) Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14: 2003–2015.

26. Bryan BA, Dunstedt E, Mitchell DC, Walsh TE, Noma K, et al. (2010) RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J 24: 3188–3195.

27. Marinissen MJ, Chiarieatto M, Tanou T, Bernard O, Narumiya S, et al. (2004) The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell 14: 29–41.

28. Shatanawi A, Romero MJ, Iddings JA, Chandra S, Umapathy NS, et al. (2011) Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am J Physiol Cell Physiol 300: C1181–1192.

29. Hong SY, Jeon YM, Lee HJ, Kim JG, Baek JA, et al. (2010) Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol 48: 233–239.

30. Ye Y, Hu SJ, Li L (2009) Inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: involvement of the RhoA/Rho kinase pathway. FEBS Lett 583: 2997–3003.

31. Daugherty A, Manning MW, Cassis LA (2000) Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105: 1605–1612.

32. Kong TY, Jung SY, Kim JW, Lee SH, Lee JH, et al. (2012) Phloroglucinol inhibits the biosactivities of endothelial progenitor cells and suppresses tumor angiogenesis in LLC-tumor-bearing mice. PLoS One 7: e33618.

33. Raikkonen J, Monkkonen H, Avrdla S, Monkkonen J (2010) Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem Pharmacol 79: 777–783.

34. Nogawa M, Yuasa T, Kimura S, Kuroda J, Segawa H, et al. (2005) Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res 15: 1–9.

35. Raikkonen J, Monkkonen H, Avrdla S, Monkkonen J (2010) Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem Pharmacol 79: 777–783.

36. Kwon YH, Jung SY, Kim JW, Lee SH, Lee JH, et al. (2012) Phloroglucinol inhibits the biosactivities of endothelial progenitor cells and suppresses tumor angiogenesis in LLC-tumor-bearing mice. PLoS One 7: e33618.

37. Routhier A, Astuccio M, Lahey D, Monfredo N, Johnson A, et al. (2010) Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol Rep 23: 661–667.

38. Routhier A, Astuccio M, Lahey D, Monfredo N, Johnson A, et al. (2010) Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol Rep 23: 661–667.

39. Bryan BA, D’Amore PA (2007) What tangled webs they weave: Rho-GTPase control of angiogenesis. Cell Mol Life Sci 64: 2053–2065.

40. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420: 674–681.

41. Bryan BA, D’Amore PA (2007) What tangled webs they weave: Rho-GTPase control of angiogenesis. Cell Mol Life Sci 64: 2053–2065.

42. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420: 674–681.

43. Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Rodriguez-Vita J, et al. (2008) RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis in vivo. Cancer Res 68: 21–30.

44. Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Rodriguez-Vita J, et al. (2008) RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis in vivo. Cancer Res 68: 21–30.

45. Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Rodriguez-Vita J, et al. (2008) RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis in vivo. Cancer Res 68: 21–30.

46. Rodriquez-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Rodriguez-Vita J, et al. (2008) RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis in vivo. Cancer Res 68: 21–30.

47. Rodriquez-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Rodriguez-Vita J, et al. (2008) RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis in vivo. Cancer Res 68: 21–30.

48. Rodriquez-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Rodriguez-Vita J, et al. (2008) RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis in vivo. Cancer Res 68: 21–30.